BMY Shares Drop 2.82% with $550M Volume Ranking 179th as $300M Immunology Spinoff Drives Strategic Shift

On September 12, 2025, , , ranking 179th in the market. The stock’s decline follows recent corporate developments, . The new entity, focused on autoimmune therapies, marks a strategic pivot for the pharma giant, which has been restructuring its portfolio to address patent expirations and competitive pressures.

Key news influencing the stock includes the appointment of as Chief Medical Officer, a move aimed at strengthening R&D leadership. Additionally, the company’s Q2 earnings report highlighted ongoing challenges in offsetting generic drug competition, despite recent gains in select therapeutic areas. Analysts remain cautious, with some suggesting that Bristol’s cost-cutting measures and pipeline advancements could stabilize long-term growth but may not immediately reverse near-term headwinds.

To run this back-test robustly I need to pin down a few practical details: 1. Universe • Which stock universe should we rank for volume each day? – All U.S. listed common shares (≈ 5 000 tickers) – S&P 500 constituents only – Another list you have in mind 2. Price used for entry/exit • Buy at the same day’s close and sell next day’s close (T + 1)? • Or buy next day’s open and sell that day’s close? 3. Trading-cost assumptions (commissions, slippage) – include them or keep the test frictionless? Once I have these three items I can lay out a data-collection plan and run the back-test.